Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $173.0 million.

  • Denali Therapeutics' Non-Current Assets fell 70.43% to $173.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.0 million, marking a year-over-year decrease of 70.43%. This contributed to the annual value of $509.7 million for FY2024, which is 467.77% up from last year.
  • Denali Therapeutics' Non-Current Assets amounted to $173.0 million in Q3 2025, which was down 25.27% from $231.5 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Non-Current Assets peaked at $607.5 million during Q1 2024, and registered a low of $81.7 million during Q2 2023.
  • In the last 3 years, Denali Therapeutics' Non-Current Assets had a median value of $231.5 million in 2025 and averaged $311.2 million.
  • Per our database at Business Quant, Denali Therapeutics' Non-Current Assets crashed by 82.66% in 2022 and then surged by 621.67% in 2024.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Non-Current Assets stood at $506.9 million in 2021, then slumped by 82.66% to $87.9 million in 2022, then rose by 2.11% to $89.8 million in 2023, then soared by 467.77% to $509.7 million in 2024, then plummeted by 70.43% to $173.0 million in 2025.
  • Its last three reported values are $173.0 million in Q3 2025, $231.5 million for Q2 2025, and $392.7 million during Q1 2025.